CD47 and ovarian carcinoma: To test whether mAb treatment would be a viable therapeutic approach, we designed in vitro phagocytosis assays and in vivo experiments similar to the shRNA knockdown experiments and evaluated the efficacy of an anti-CD47 mAb as a therapeutic in ovarian cancer, especially in preventing the early seeding events.